Login or sign up
For business
Average ratingAverage
3.9/ 5

Based on 9 reviews

533%
422%
344%
20%
10%
Ask AI

Ask AI about Neutrolis

Generated with AI from 9 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Neutrolis

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapy on the market that effectively targets and removes NETs.

Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.

Categories
Biotechnology